90004-09-4

Basic information

• Product Name: 7-AMINO-4(1H)-QUINAZOLINONE
• Synonyms: 7-AMINO-4-HYDROXYQUINONAZOLINE;7-AMINO-4(1H)-QUINAZOLINONE;7-AMINO-QUINAZOLIN-4-OL;7-AMINOQUINAZOLIN-4-ONE;7-Amino-4(1H)-quinazolinone 7-Aminoquinazolin-4-one;4(3H)-Quinazolinone, 7-amino;7-AMinoquinazolin-4(3H)-one;7-AMinoquinazolin-4(1H)-one
• CAS NO: 90004-09-4
• Molecular Formula: C₈H₇N₃O
• Molecular Weight: 161.16
• Product Categories: pharmacetical;API intermediates
• Mol File: 90004-09-4.mol
• Article Data: 8

Chemical Properties

• Melting Point: 315 °C
• Boiling Point: 392.9 °C at 760 mmHg
• Flash Point: 191.4 °C
• Appearance: /
• Density: 1.49 g/cm³
• Vapor Pressure: 2.21E-06mmHg at 25°C
• Refractive Index: 1.734
• PKA: 2.27±0.20(Predicted)
• CAS DataBase Reference: 7-AMINO-4(1H)-QUINAZOLINONE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-AMINO-4(1H)-QUINAZOLINONE(90004-09-4)
• EPA Substance Registry System: 7-AMINO-4(1H)-QUINAZOLINONE(90004-09-4)

Safety Data

• Hazardous Substances Data: 90004-09-4(Hazardous Substances Data)

Usage

General Description

7-Amino-4(1H)-quinazolinone is a chemical compound with the molecular formula C8H7N3O. It is a derivative of quinazolinone and contains an amino group at the 7th position of the quinazolinone ring. 7-AMINO-4(1H)-QUINAZOLINONE is a heterocyclic organic molecule and has been used in the development of various therapeutic agents and pharmaceutical drugs. It has also shown potential in various biological and pharmacological studies, exhibiting anti-inflammatory, antioxidant, and anticancer properties. Furthermore, 7-Amino-4(1H)-quinazolinone has been the subject of structural and biological investigations, making it an important compound in medicinal chemistry research and drug discovery.

InChI:InChI=1/C8H7N3O/c9-5-1-2-6-7(3-5)10-4-11-8(6)12/h1-4H,9H2,(H,10,11,12)

Upstream product

• 20872-93-9 7-nitroquinazolin-4(3H)-one 
• 619-17-0 4-Nitroanthranilic acid 
• 20872-93-9 4-hydroxy-7-nitroquinazoline 
• 20872-93-9 7-nitroquinazolin-4-one 

Downstream Products

• 16064-25-8 7-hydroxyquinazolin-4-one 
• 202197-78-2 4-chloro-7-iodoquinazoline 
• 202197-79-3 (1-benzyl-1H-indazol-5-yl)-(7-iodoquinazolin-4-yl)-amine hydrochloride 
• 887128-75-8 4-(4-oxo-3,4-dihydro-quinazolin-7-ylcarbamoyl)-4-phenyl-piperidine-1-carboxylic acid 9H-fluoren-9-ylmethyl ester 
• 887128-65-6 [3-(3,4-dichloro-phenyl)-3-(4-oxo-3,4-dihydro-quinazolin-7-ylcarbamoyl) propyl]-carbamic acid tert-butyl ester 
• 202197-77-1 7-iodo-1H-quinazolin-4-one 

Relevant articles and documents

Structure-based drug design, synthesis and screening of MmaA1 inhibitors as novel anti-TB agents

Abstract: Tuberculosis is one of the leading causes of death across the world. The treatment regimens for tuberculosis are well established, but still the control of the disease faces many challenges such as lengthy treatment protocols, drug resistance an

Antiviral agents

This invention relates to compounds of formula I their salts, and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions comprising these compounds and their use in the treatment of picornavirus infections in mammals, as well as nove

Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account

Two closely related scaffolds were identified through an uHTS campaign as desirable starting points for the development of Rho-Kinase (ROCK) inhibitors. Here, we describe our hit-to-lead evaluation process which culminated in the rapid discovery of potent leads such as 22 which successfully demonstrated an early in vivo proof of concept for anti-hypertensive activity.